SCHEMBL10163089

SCHEMBL10163089

COc1cc2ccccc2cc1NC(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.58
MAOB P27338 1/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
TACR3 P29371 1/20 0.57
CA1 P00915 3/20 0.54
CA2 P00918 3/20 0.54
ACHE P22303 3/20 0.54
MEN1 O00255 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
PLAU P00749 1/20 0.51
CTSV O60911 1/20 0.49
CTSL P07711 1/20 0.49
MGLL Q99685 1/20 0.49
POLB P06746 1/20 0.48
TP53 P04637 1/20 0.47
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4210145 0.84 KMT2A (0.56) KMT2AMAOBNPC1RAB9ATACR3
SCHEMBL9524227 0.82 NPC1 (0.56) KMT2AMAOBNPC1RAB9ATACR3
SCHEMBL5223936 0.82 KMT2A (0.62) KMT2AMAOBNPC1RAB9ATACR3
SCHEMBL5783658 0.82 HTT (0.59) KMT2AMAOBNPC1RAB9ATACR3
SCHEMBL7268166 0.81 MAOB (0.61) MAOBNPC1RAB9ATACR3L3MBTL1
SCHEMBL6786224 0.80 POLB (0.57) KMT2AMAOBNPC1MEN1POLB
SCHEMBL10489859 0.80 KDM4E (0.60) KMT2ANPC1RAB9ATACR3MEN1
SCHEMBL29950865 0.80 NPC1 (0.53) KMT2AMAOBNPC1RAB9ATACR3
SCHEMBL29953911 0.80 KMT2A (0.60) KMT2AMAOBNPC1RAB9ATACR3
SCHEMBL27401772 0.79 KMT2A (0.53) KMT2AMAOBNPC1RAB9ATACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329866-A1 OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2014-11-06 US disclosed
US-20140329866-A1 OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2014-11-06 US disclosed
US-8841330-B2 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC (US) 2014-09-23 US disclosed
US-8841330-B2 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC (US) 2014-09-23 US disclosed
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHERCARE LLC (US) 2012-10-25 US disclosed
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHERCARE LLC (US) 2012-10-25 US disclosed
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHERCARE LLC (US) 2012-06-07 US disclosed
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHERCARE LLC (US) 2012-06-07 US disclosed
US-8124630-B2 ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC (US) 2012-02-28 US disclosed
US-20120040986-A1 OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS RIEDL BERND (DE) 2012-02-16 US disclosed
US-20080108672-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors BAYER HEALTHCARE LLC 2008-05-08 US disclosed
US-20080108672-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors BAYER HEALTHCARE LLC 2008-05-08 US disclosed
US-7351834-B1 ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2008-04-01 US disclosed
US-7351834-B1 ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2008-04-01 US disclosed
US-20080032979-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors BAYER HEALTHCARE LLC 2008-02-07 US disclosed
US-20080032979-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors BAYER HEALTHCARE LLC 2008-02-07 US disclosed
US-20080027061-A1 omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors BAYER HEALTHCARE LLC 2008-01-31 US disclosed
US-20080027061-A1 omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors BAYER HEALTHCARE LLC 2008-01-31 US disclosed
US-7235576-B1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2007-06-26 US disclosed
US-7235576-B1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108672-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors BRAF, RAF1, ARAF KMT2A 1777/4885MAOB 1671/4885NPC1 1094/4885
US-20080032979-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors BRAF, NRAS, RAF1 KMT2A 1673/4885MAOB 918/4885NPC1 1956/4885
US-20080027061-A1 omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors MAPK1, MAPK8, MAPK3 KMT2A 2813/4885MAOB 2054/4885NPC1 569/4885
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 KMT2A 2870/4885MAOB 1844/4885NPC1 2972/4885
US-20140329866-A1 OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF KMT2A 2458/4885MAOB 2281/4885NPC1 1765/4885
US-20120040986-A1 OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, NRAS, RAF1 KMT2A 1970/4885MAOB 1449/4885NPC1 1016/4885
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF KMT2A 1777/4885MAOB 1671/4885NPC1 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.